Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Placebo-Controlled Study to Evaluate the Effect of a Single Dose of CVN058 on Mismatch Negativity in Subjects With Stable Schizophrenia

NCT03669250 is registered in ClinicalTrials.gov with Cerevance Alpha, Inc. as lead sponsor.

NCT NCT03669250
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03669250 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Placebo-Controlled Study to Evaluate the Effect of a Single Dose of CVN058 on Mismatch Negativity in Subjects With Stable Schizophrenia
Lead sponsor
Cerevance Alpha, Inc.
Phase
Phase 1
Overall status
Completed
Start date
November 9, 2018
Completion date
March 6, 2020
Enrollment
22 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia